Novexel

Novexel discovered and developed novel anti-bacterials and anti-fungals. Formed as a spin-out of Aventis Pharma, a subsidiary of Sanofi-Aventis, it inherited an advanced portfolio of anti-infective programmes and intellectual property. The company was acquired by AstraZeneca for up to $505 million in March 2010.